References

Key articles

Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2017. September 2018 [internet publication].

Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.

American Congress of Obstetricians and Gynecologists. Committee opinion no. 506: expedited partner therapy in the management of gonorrhea and chlamydia by obstetrician-gynecologists. Obstet Gynecol. 2011 Sep;118(3):761-6.

Reference articles

1. Torrone E, Papp J, Weinstock H. Prevalence of Chlamydia trachomatis genital infection among persons aged 14-39 years--United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014 Sep 26;63(38):834-8.

2. Nwokolo NC, Dragovic B, Patel S, et al. 2015 UK national guideline for the management of infection with Chlamydia trachomatis. Int J STD AIDS. 2016 Mar;27(4):251-67.

3. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2017. September 2018 [internet publication].

4. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.

5. Bachmann NL, Polkinghorne A, Timms P. Chlamydia genomics: providing novel insights into chlamydial biology. Trends Microbiol. 2014 Aug;22(8):464-72.

6. Elwell C, Mirrashidi K, Engel J. Chlamydia cell biology and pathogenesis. Nat Rev Microbiol. 2016 Jun;14(6):385-400.

7. Scidmore MA. Cultivation and laboratory maintenance of Chlamydia trachomatis. Curr Protoc Microbiol. 2005 Jul;Chapter 11:Unit 11A.1.

8. Mertz KJ, McQuillan GM, Levine WC, et al. A pilot study of the prevalence of chlamydia infection in a national household survey. Sex Transm Dis. 1998 May;25(5):225-8.

9. Stamm WE. Chlamydia trachomatis infections: progress and problems. J Infect Dis. 1999 Mar;179(suppl 2):S380-3.

10. Cecil JA, Howell MR, Tawes JJ, et al. Features of Chlamydia trachomatis and Neisseria gonorrhoeae infection in male Army recruits. J Infect Dis. 2001 Nov 1;184(9):1216-9.

11. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae - 2014. MMWR Recomm Rep. 2014 Mar 14;63(RR-02):1-19.

12. Moncada J, Schachter J, Liska S, et al. Evaluation of self-collected glans and rectal swabs from men who have sex with men for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of nucleic acid amplification tests. J Clin Microbiol. 2009 Jun;47(6):1657-62.

13. Cosentino LA, Campbell T, Jett A, et al. Use of nucleic acid amplification testing for diagnosis of anorectal sexually transmitted infections. J Clin Microbiol. 2012 Jun;50(6):2005-8.

14. Hoebe CJ, Rademaker CW, Brouwers EE, et al. Acceptability of self-taken vaginal swabs and first-catch urine samples for the diagnosis of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae with an amplified DNA assay in young women who attend a public health sexually transmitted disease clinic. Sex Transm Dis. 2006 Aug;33(8):491-5.

15. Whitlock GG, Gibbons DC, Longford N, et al. Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits. Int J STD AIDS. 2018 Apr;29(5):474-82.

16. Gaydos CA, Ferrero DV, Papp J. Laboratory aspects of screening men for Chlamydia trachomatis in the new millennium. Sex Transm Dis. 2008 Nov;35(11 suppl):S45-50.

17. Kelly H, Coltart CEM, Pant Pai N, et al. Systematic reviews of point-of-care tests for the diagnosis of urogenital Chlamydia trachomatis infections. Sex Transm Infect. 2017 Dec;93(S4):S22-S30.

18. May L, Ware CE, Jordan JA, et al. A randomized controlled trial comparing the treatment of patients tested for chlamydia and gonorrhea after a rapid polymerase chain reaction test versus standard of care testing. Sex Transm Dis. 2016 May;43(5):290-5.

19. Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017 Aug;17(8):e235-79.

20. LeFevre ML; U.S. Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Dec 16;161(12):902-10.

21. American Academy of Family Physicians. Summary of recommendations for clinical preventive services. July 2017 [internet publication].

22. National Institute for Health and Care Excellence. Antenatal care for uncomplicated pregnancies. January 2017 [internet publication].

23. Lanjouw E, Ouburg S, de Vries HJ, et al. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS. 2016 Apr;27(5):333-48.

24. Royal Australian College of General Practitioners. Chapter 6.2 Sexually transmissible infections. Guidelines for preventive activities in general practice 9th edition. 2018 [internet publication].

25. Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis. 2012 Jul;55(1):82-8.

26. Cluver C, Novikova N, Eriksson DO, et al. Interventions for treating genital Chlamydia trachomatis infection in pregnancy. Cochrane Database Syst Rev. 2017;(9):CD010485.

27. Centers for Disease Control and Prevention. Expedited partner therapy in the management of sexually transmitted diseases. 2006 [internet publication].

28. American Congress of Obstetricians and Gynecologists. Committee opinion no. 506: expedited partner therapy in the management of gonorrhea and chlamydia by obstetrician-gynecologists. Obstet Gynecol. 2011 Sep;118(3):761-6.

29. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002 Sep;29(9):497-502.

30. World Health Organization. WHO guidelines for the treatment of Chlamydia trachomatis. 2016 [internet publication].

31. Centers for Disease Control and Prevention. Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep. 2008 Nov 7;57(RR-9):1-83.

32. Ahmadi MH, Mirsalehian A, Bahador A. Prevalence of genital Chlamydia trachomatis in Iran: a systematic review and meta-analysis. Pathog Glob Health. 2015 Sep;109(6):290-9.

33. Denison HJ, Curtis EM, Clynes MA, et al. The incidence of sexually acquired reactive arthritis: a systematic literature review. Clin Rheumatol. 2016 Nov;35(11):2639-48.

34. Carter JD, Inman RD. Chlamydia-induced reactive arthritis: hidden in plain sight? Best Pract Res Clin Rheumatol. 2011 Jun;25(3):359-74.

35. Rich E, Hook EW 3rd, Alarcón GS, et al. Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Arthritis Rheum. 1996 Jul;39(7):1172-7.

36. Darling EK, McDonald H. A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. J Midwifery Womens Health. 2010 Jul-Aug;55(4):319-27.

37. Zhu H, Shen Z, Luo H, et al. Chlamydia trachomatis infection-associated risk of cervical cancer: a meta-analysis. Medicine (Baltimore). 2016 Mar;95(13):e3077.

Use of this content is subject to our disclaimer